Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive
  • Overview
  • Investor News 2009
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2009
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Sustainability
• Press

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2009

Search

Here you find Investor News of year 2009. Ad-hoc messages issued in year 2008 can be found here.
Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Thursday December 10, 2009

Clinical Programs with Riociguat in Pulmonary Hypertension Well on Track

Encouraging top-line data from the first Phase II study in pulmonary hypertension owing to interstitial lung disease (PH-ILD) / First Phase II study in pulmonary hypertension owing to chronic obstructive pulmonary disease (PH-COPD) successfully completed

Monday December 07, 2009

Visanne® cleared for market launch in Europe as new treatment option for endometriosis

Sunday December 06, 2009

Treatment of Venous Thromboembolism (VTE):

Phase III EINSTEIN-Extension Study of Bayer's Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE

Impressive 82% Relative Risk Reduction (RRR) in the Recurrence of Symptomatic VTE over Patients Treated with Placebo / Positive Benefit-Risk profile for Rivaroxaban Confirmed / First Phase III Data in the Chronic Setting to be Presented as a Late-Breaker at the Annual Meeting of the American Society of Hematology / Ongoing Discussions with FDA on Complete Response Letter for VTE Prevention After Total Knee and Hip Replacement Surgery

Tuesday December 01, 2009

Development of new BiTE antibody for treatment of solid tumors:

Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy

Tuesday December 01, 2009

Bayer's Betaferon® approved in China for Treatment of Multiple Sclerosis

Launch planned by mid 2010

Monday November 30, 2009

Bayer Starts Phase III Trial with Florbetaben

Detection of beta-Amyloid plaques in Alzheimer patients possible / Florbetaben could improve current diagnostic tools

Thursday November 19, 2009

Positive Results from Chronic Study with Bayer's Rivaroxaban Will be Presented As a Late Breaker at ASH 2009

Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE

Monday November 02, 2009

Successful purchase of trait platform with extensive product pipeline:

Bayer CropScience completes acquisition of biotech company Athenix Corp.

Purchase price of USD 365 million plus milestones

Tuesday October 27, 2009

Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:

Bayer back on the uptrend

HealthCare again strong - weak quarter at CropScience - MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed

Friday October 23, 2009

Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer

Thursday October 22, 2009

Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:

The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market

Friday October 09, 2009

Improvement in orders

Bayer MaterialScience AG ends reduced working hours at German sites

Rates of pay to be raised again / Solidarity-based solution has proved its worth / Opening clause in collective agreement applied from February to the end of October 2009

Monday October 05, 2009

Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):

Bayer's novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding

Results also confirm significant improvement in blood iron levels

Wednesday September 30, 2009

Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer

Preliminary results require further analysis and interpretation

Wednesday September 23, 2009

Phase II Study in Advanced Breast Cancer:

Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival

First presentation of results at joint ECCO-ESMO congress in Berlin, Germany

Tuesday September 22, 2009

Results of a Phase II study in Renal Cell Carcinoma (RCC):

Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients

Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009

Thursday September 17, 2009

Greater focus on future technologies:

Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018

BioScience sales of EUR 1.4 billion targeted for 2018 / Biotech licensing agreements tap into business potential in excess of EUR 500 million / Peak sales potential of new crop protection actives raised to EUR 1.25 billion

Thursday September 17, 2009

Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:

Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009

Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions

Tuesday September 15, 2009

Bayer Supervisory Board decides company's future management line-up:

Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010

Werner Wenning extends his contract by eight months / CFO Klaus Kühn to retire on April 30, 2010 / Werner Baumann to be new CFO / BHC CEO Arthur J. Higgins to leave Bayer at his own request

Thursday September 03, 2009

Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients

Phase III compound represents potential therapy for life-threatening condition

Wednesday September 02, 2009

Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.

Bayer subsidiary Intendis expands presence in the U.S. / Asset purchase agreement signed for marketed prescription products Desonate® and NeoBenz® Micro

Sunday August 30, 2009

Bayer Committed to Prevention of Arterial Thrombosis:

Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)

ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation / Bayer Schering Pharma supports Thrombosis Research Institute's launch of GARFIELD - a global patient Registry to evaluate 'real life' outcomes in the prevention of stroke in patients with Atrial Fibrillation / Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need.

Wednesday August 19, 2009

Trait platform with extensive product pipeline to deliver innovative solutions for farmers:

Bayer CropScience acquires US biotech company Athenix Corp.

Wednesday August 19, 2009

New Levitra® formulation submitted for registration in the EU

First orodispersible tablet for the treatment of erectile dysfunction

Wednesday July 29, 2009

Interim report for the second quarter of 2009:

Bayer robust in a difficult environment

HealthCare strong - further growth at CropScience - MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) / Earnings targets for full year 2009 confirmed

Wednesday July 22, 2009

Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer

Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies

Tuesday July 21, 2009

Long-term cooperation with leading Australian research institute CSIRO:

Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cereals

Superior solutions for wheat farmers could be available as early as 2015

Thursday July 16, 2009

Bayer MaterialScience lifts force majeure for TDI in Europe

Tuesday July 14, 2009

New Drug Application for Rivaroxaban in the U.S.:

Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA

Monday July 13, 2009

International Conference on Alzheimer's Disease (ICAD):

Bayer presents positive Phase II data with florbetaben

Potential to visualize beta-Amyloid plaques in Patients with Alzheimer's disease demonstrated / Florbetaben may innovate the diagnostic capabilities

Thursday July 09, 2009

Expansion of diabetes portfolio in growth market China:

Bayer acquires exclusive rights to Bioton's insulin SciLin®

Wednesday July 08, 2009

Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.

FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding

Tuesday July 07, 2009

Bayer MaterialScience declares force majeure for TDI in Europe

Wednesday July 01, 2009

Bayer files patent infringement lawsuit against Teva

Monday June 29, 2009

Bayer CropScience and Monsanto sign cross licensing agreement on herbicide tolerance traits in rapeseed/canola

Thursday June 25, 2009

New choices for corn and soybean farmers worldwide:

Bayer CropScience and DuPont expand collaboration with broad license agreements

Tuesday June 02, 2009

Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement

Monday June 01, 2009

Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer

Saturday May 30, 2009

45th American Society of Clinical Oncology Annual Meeting (ASCO):

Bayer Schering Pharma Announces New Data on Novel Anti-cancer Compound BAY 73-4506

Thursday May 28, 2009

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:

U.S. FDA Issues Complete Response Letter for Rivaroxaban

No new clinical or non-clinical studies to be conducted as a pre-requisite for approval

Thursday May 28, 2009

Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer

Friday May 22, 2009

Milestone for the cotton-pipeline

U.S. Department of Agriculture grants approval for Bayer CropScience's GlyTol

Wednesday May 20, 2009

Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer

Tuesday May 19, 2009

American Thoracic Society (ATS) congress, San Diego, USA:

Bayer Schering Pharma presents positive results of phase II study with Riociguat

Friday May 15, 2009

Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

Thursday May 14, 2009

Qlaira® - innovative estradiol-based oral contraceptive available in Europe from May onwards

A new oral contraceptive delivering the same estrogen as produced by the female body

Tuesday May 05, 2009

Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch

Thursday April 30, 2009

Bayer and Regeneron extend development program for VEGF Trap-Eye

Two phase III studies in Central Retinal Vein Occlusion (CRVO) to begin in the second half of this year

Wednesday April 29, 2009

Bayer interim report for the first quarter of 2009

CropScience and Pharmaceuticals continue on a path of growth - Slump in business at MaterialScience leaves a distinct mark

Group sales: EUR 7,895 million (minus 7.5 percent) / EBITDA before special items: EUR 1,695 million (minus 22.4 percent) / EBIT before special items: EUR 1,017 million (minus 32.1 percent) / Net cash flow: EUR 693 million (plus 31.3 percent)

Tuesday April 28, 2009

Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer

Monday April 27, 2009

Phase III Trial of Nexavar® in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint

Study stopped based on interim analysis

Tuesday March 31, 2009

Bayer HealthCare and Genzyme Corporation Enter New Strategic Agreement

Agreement improves profitability and strategic focus in key Bayer therapeutic areas / Licenses hematological cancer products to Genzyme / Continues co-development partnership for alemtuzumab in multiple sclerosis (MS) / Bayer maintains worldwide co-promotion rights for alemtuzumab in MS - distribution rights returned to Genzyme / Bayer to receive substantial licensing, milestone payments from Genzyme over the duration of the agreement

Monday March 23, 2009

Bayer issues corporate bond with a volume of EUR 1.3 billion

Thursday March 19, 2009

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:

U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer's rivaroxaban

Tuesday March 03, 2009

2008 earnings targets met

Bayer: corporate strategy proves effective in a difficult environment

Sales increase by 1.6 percent to EUR 32,918 million / EBITDA before special items up 2.3 percent to EUR 6,931 million / EBIT before special items up 1.3 percent to EUR 4,342 million / Net income of EUR 1,719 million (2007: EUR 4,711 million) / Further earnings growth expected at HealthCare and CropScience in 2009 / Sharp decline in earnings forecasted for MaterialScience / Significant reduction of net debt targeted

Friday February 27, 2009

Bayer proposes increased dividend for 2008 of EUR 1.40 per share

Plans to switch from bearer shares to registered shares

Thursday February 12, 2009

Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center

Monday February 09, 2009

Development of riociguat is progressing well:

Bayer Schering Pharma Starts Phase III Program of New Drug Against Pulmonary Hypertension

Wednesday January 07, 2009

Visanne® - new long-term treatment for endometriosis submitted for registration in Europe